Pharmacy verification
The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.
We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.
Compounding Pharmacy Verification Center
Who actually makes the medicine, under which registration, and how to check that yourself before you order.
Compounded medicines are prepared by pharmacies registered under section 503A or by outsourcing facilities registered under 503B, which are regulated differently. This centre explains what each registration means, what accreditation does and does not certify, and how to check a licence with the issuing board yourself.
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Get the name | A provider that will not name the pharmacy has answered your question. |
| 2 | Identify the registration class | 503A pharmacy or 503B outsourcing facility. They differ materially. |
| 3 | Check the state board licence | The board's own lookup, and confirm it is active. |
| 4 | Check FDA registration if 503B | The agency publishes the registered outsourcing facility list. |
| 5 | Ask about testing | Who tested it, for what, and can you see the certificate. |
| Claim | What it proves | What it does not prove |
|---|---|---|
| FDA-registered facility | The facility filed a registration | That any product is FDA-approved |
| PCAB accredited | A voluntary accreditation was granted | Batch quality or FDA approval |
| Licensed pharmacy | A state board issued a licence | That the licence is current — check it |
| Third-party tested | Something was tested | What was tested, or by whom, unless shown |
| USP <797> compliant | A sterile compounding standard is claimed | That it was independently audited |
| FDA-approved compounded medication | Nothing — no such category exists | Treat this claim as a red flag |
Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.
Related on this site
- How to Verify a Compounding PharmacyPharmacies
- 503A Compounding Pharmacy DirectoryPharmacies
- 503B Outsourcing Facility DirectoryPharmacies
- What PCAB Accreditation MeansPharmacies
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Compounding Pharmacy Verification ToolTools
- 503A vs 503B: A Patient Verification ChecklistJournal
- 503A vs 503B CompoundingComparisons
Related coverage
- Tesamorelin: The Peptide That Actually Has an Approval and a Trial Programme
- Pharmacy disclosure register
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Flat-Rate vs Dose-Escalating GLP-1 Pricing
- Form Health vs Found
- Form Health vs Henry Meds
- Form Health vs Hims
- Form Health vs IVIM Health
GLP-1 Semaglutide Rx. “Compounding Pharmacy Verification Center.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/pharmacies/
Quote the capture date beside a figure, not the date you read this page. Why.
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Covered brand plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Approved oral GLP-1 | $149 | $1,788 | Captured at source |
| Compounded tirzepatide, flat, 12-month | $186 | $2,232 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
Prices re-confirmed at source on 2026-08-03. The compounded row has no trial of its own; every efficacy figure on this site was collected on the approved product. Full ladder and evidence grades: the ranking.